文献速递妇产影像US

我们已完成最后一例羊膜腔穿刺了吗?无创产前检测筛查唐氏综合征的进展

Have we done our last amniocentesis? Updates on cell-free DNA for Down syndrome screening.
PubMed 文献 · Pediatr Radiol · 2018-03-17

2012年无创产前检测(NIPT)引入后,产前非整倍体筛查发生显著变化。NIPT通过二代测序分析母血中胎盘来源的胎儿游离DNA与母体游离DNA的比值,对21、18、13、X和Y染色体非整倍体进行评估。相比传统超声和血清标志物筛查,NIPT具有更高的检出率和阳性预测值,以及更低的假阳性率。NIPT已用于高危孕妇的初筛并快速扩展至所有孕妇,但结果不一致(NIPT阳性而胎儿核型正常)可由胎盘局限性非整倍体、消失的双胎、母体非整倍体或母体癌症等生物学过程导致。不推荐将NIPT用于筛查最常见非整倍体以外的染色体异常。NIPT是产前非整倍体筛查的重大进步,但并非诊断性检查,不能替代绒毛膜绒毛取样或羊膜腔穿刺等侵入性检查来确认胎儿染色体疾病。

要点

  • NIPT通过二代测序比较母胎游离DNA比值评估21、18、13、X和Y染色体非整倍体。
  • NIPT筛查高危孕妇的检出率和阳性预测值高于传统超声和血清学筛查,假阳性率更低。
  • NIPT阳性而胎儿核型正常的结果不一致可由胎盘局限性非整倍体、消失的双胎、母体非整倍体或母体癌症导致。

核心结论

  • NIPT是产前非整倍体筛查的重大进步,但并非诊断性检查,不能替代侵入性检查确认胎儿染色体疾病。

研究设计与样本

  • 综述,阐述NIPT的原理、临床应用及局限性,未报告系统检索范围与纳入文献数量。

诊断标准与关键数值

  • NIPT利用二代测序比较母体与胎儿游离DNA在目标染色体(21、18、13、X和Y)上的比值来评估染色体非整倍体。
  • 与传统超声和血清标志物筛查相比,NIPT具有更高的检出率和阳性预测值,以及更低的假阳性率。
  • 不推荐将NIPT用于筛查最常见非整倍体以外的染色体异常。

临床应用与阅片要点

  • 原文未据此给出具体阅片或报告操作推荐。

局限性

  • NIPT结果不一致(NIPT非整倍体阳性而胎儿核型正常)可由胎盘局限性非整倍体、消失的双胎、母体非整倍体或母体癌症等生物学过程导致。
  • NIPT并非诊断性检查,不能替代绒毛膜绒毛取样或羊膜腔穿刺来确认胎儿染色体疾病。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

Prenatal aneuploidy screening changed significantly in 2012 when cell-free fetal deoxyribonucleic acid (DNA) was introduced as a noninvasive prenatal test. A noninvasive prenatal test detects cell free fragments of fetal DNA from the placenta circulating in maternal blood that coexist with cell-free DNA (cfDNA) of maternal origin. Using next-generation sequencing, the noninvasive prenatal test compares maternal and fetal cfDNA ratios for chromosomes of interest (i.e., 21, 18, 13, X, and Y) to assess chromosomal aneuploidy. Compared to traditional screening using ultrasound and serum markers, the noninvasive prenatal test has superior test characteristics, including a higher detection rate and positive predictive value, and a lower false-positive rate. The noninvasive prenatal test is already used for primary screening in high-risk women and is rapidly expanding to all women. Given its increasing use, understanding the noninvasive prenatal test's limitations is critical. Discordant results (i.e. noninvasive prenatal test is positive for aneuploidy with a normal fetal karyotype) can occur because of biological processes such as aneuploidy confined to the placenta, a vanished twin, maternal aneuploidy or maternal cancer. Use of the noninvasive prenatal test for screening beyond the most common aneuploidies is not recommended. The noninvasive prenatal test is a major advance in prenatal aneuploidy screening but it is not diagnostic and does not replace invasive testing (i.e. chorionic villous sampling or amniocentesis) for confirmation of fetal chromosomal disorders.

来源:Pediatr Radiol,查看原文。版权归原作者所有。

引用

  1. Gray KJ, Wilkins-Haug LE. Have we done our last amniocentesis? Updates on cell-free DNA for Down syndrome screening. Pediatr Radiol. 2018. PMID: 29550862. doi:10.1007/s00247-017-3958-y

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。